Emerging immunotherapies for bladder cancer

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Current Opinion in Oncology

• Publication date

  2015-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/CCO.0000000000000177PMID 25811346PMCID PMC7709951
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.

  2017cited by this paper
• A phase II study of cabozantinib in patients (pts) with relapsed/refractory metastatic urothelial carcinoma (mUC)

  2016cited by this paper
• VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors

  2015cited by this paper
• A systematic review and meta-analysis of clinical trials of bladder-sparing trimodality treatment for muscle-invasive bladder cancer (MIBC).

  2015cited by this paper
• The PTEN pathway in Tregs functions as a critical driver of the immunosuppressive tumor microenvironment and tolerance to apoptotic cells

  2015cited by this paper
• A phase I study of TRC105 anti‐endoglin (CD105) antibody in metastatic castration‐resistant prostate cancer

  2015cited by this paper
• Significance of MUC1 in bladder cancer

  2015cited by this paper
• PD-L1 expression in mononuclear cells and not in tumor cells, correlated with prognosis in metastatic urothelial carcinoma.

  2014cited by this paper
• MAGE-A3 is highly expressed in a cancer stem cell-like side population of bladder cancer cells.

  2014cited by this paper
• The geriatrics and genetics behind bladder cancer.

  2014cited by this paper
• Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

  2014cited by this paper
• Exploiting the curative potential of adoptive T‐cell therapy for cancer

  2014cited by this paper
• Cancer Immunotherapy Highlights from the 2014 ASCO Meeting

  2014cited by this paper
• Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma.

  2014cited by this paper
• Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).

  2014cited by this paper
• Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer

  2014cited by this paper
• Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis

  2014cited by this paper
• Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine

  2014cited by this paper
• Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder.

  2014cited by this paper
• Trial Watch

  2014cited by this paper
• Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).

  2014cited by this paper
• Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).

  2014cited by this paper
• MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

  2014cited by this paper
• Agonistic CD 40 Antibodies and Cancer Therapy

  2013cited by this paper
• Immunogenic cell death in cancer therapy.

  2013cited by this paper
• Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

  2013cited by this paper
• OX40 is a potent immune-stimulating target in late-stage cancer patients.

  2013cited by this paper
• CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients

  2013cited by this paper
• Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer

  2013cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• Oncology meets immunology: the cancer-immunity cycle.

  2013cited by this paper
• Agonistic CD40 Antibodies and Cancer Therapy

  2013cited by this paper
• Urinary Bladder Cancer Susceptibility Markers. What Do We Know about Functional Mechanisms?

  2013cited by this paper
• Microenvironmental regulation of tumor progression and metastasis

  2013cited by this paper
• HER2 expression in patients (pts) with surgically resected urothelial cancer at high risk of recurrence screened for the phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2.

  2013cited by this paper
• Therapeutic cancer vaccines: past, present, and future.

  2013cited by this paper
• The secret ally: immunostimulation by anticancer drugs

  2012cited by this paper
• Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer

  2012cited by this paper
• Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Poxviral vectors for cancer immunotherapy

  2012cited by this paper
• Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma

  2012cited by this paper
• Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986.

  2012cited by this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cited by this paper
• Neoadjuvant and adjuvant chemotherapy approaches for invasive bladder cancer.

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial.

  2011cited by this paper
• Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice.

  2011cited by this paper
• Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

  2011cited by this paper
• Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccines

  2011cited by this paper
• Antibody-Targeted NY-ESO-1 to Mannose Receptor or DEC-205 In Vitro Elicits Dual Human CD8+ and CD4+ T Cell Responses with Broad Antigen Specificity

  2011cited by this paper
• Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

  2011cited by this paper
• A phase I study of TRC105 (anti-CD105 [endoglin] antibody) in metastatic castration-resistant prostate cancer (mCRPC).

  2011cited by this paper
• A Pilot Study of MUC-1/CEA/TRICOM Poxviral-Based Vaccine in Patients with Metastatic Breast and Ovarian Cancer

  2011cited by this paper
• Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody

  2011cited by this paper
• Signaling through OX40 enhances antitumor immunity.

  2010cited by this paper
• Excision Repair Cross-Complementing Group 1 May Predict the Efficacy of Chemoradiation Therapy for Muscle-Invasive Bladder Cancer

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial

  2010cited by this paper
• Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• The PD‐1 pathway in tolerance and autoimmunity

  2010influential reference
• AdCD40L Immunogene Therapy for Bladder Carcinoma—The First Phase I/IIa Trial

  2010cited by this paper
• PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

  2010cited by this paper
• Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice.

  2010cited by this paper
• Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients

  2009cited by this paper
• Role of Polysomy 17 in Transitional Cell Carcinoma of the Bladder: Immunohistochemical Study of HER2/neu Expression and FISH Analysis of c-erbB-2 Gene and Chromosome 17

  2009cited by this paper
• Costimulatory molecule B7-H1 on the immune escape of bladder cancer and its clinical significance

  2009cited by this paper
• T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with Survival

  2008cited by this paper
• The contrasting role of B7-H3

  2008cited by this paper
• Immune Responses Detected in Urothelial Carcinoma Patients After Vaccination With NY-ESO-1 Protein Plus BCG and GM-CSF

  2008cited by this paper
• PD-1 and its ligands in tolerance and immunity.

  2008cited by this paper
• The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection

  2007influential reference
• Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement.

  2007cited by this paper
• Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers

  2007cited by this paper
• PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomata

  2007cited by this paper
• Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

  2007cited by this paper
• Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

  2006cited by this paper
• Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.

  2006cited by this paper
• Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials.

  2006cited by this paper
• Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration.

  2005cited by this paper
• Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration

  2005cited by this paper
• Cancer-testis antigen expression in bladder cancer.

  2005cited by this paper
• The B7 family member B7-H3 preferentially down-regulates T helper type 1–mediated immune responses

  2003cited by this paper
• Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer.

  2003cited by this paper
• Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

  2003cited by this paper
• Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis.

  2003cited by this paper
• B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production.

  2001cited by this paper
• B7-H3: A costimulatory molecule for T cell activation and IFN-γ production

  2001cited by this paper
• Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

  2000cited by this paper
• Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

  1997cited by this paper
• A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

  1992cited by this paper
• A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.

  1992cited by this paper
• A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors.

  1990cited by this paper

• Tumor-Infiltrating Immune Cells in Non-Muscle-Invasive Bladder Cancer: Prognostic Implications, Predictive Value, and Future Perspectives

  2025cites this paper
• Real-world data on avelumab in first-line maintenance therapy for advanced or metastatic urothelial carcinoma: the SOGUG-AVELUMAB RWD study

  2025cites this paper
• Glycan-based therapeutic approaches for bladder cancer: Overcoming clinical barriers.

  2025cites this paper
• Complete Response after Avelumab Maintenance Therapy: Successful Management of Metastatic Urothelial Carcinoma

  2025cites this paper
• Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25).

  2024cites this paper
• Comprehensive analysis of the PD-L1 and immune infiltrates of N6-methyladenosine related long non-coding RNAs in bladder cancer

  2022cites this paper
• Prognostic values of the immune microenvironment-related non-coding RNA IGF2BP2-AS1 in bladder cancer

  2022cites this paper
• The feasibility of proteomics sequencing based immune-related prognostic signature for predicting clinical outcomes of bladder cancer patients

  2022cites this paper
• Avelumab First-Line Maintenance Treatment in Advanced Bladder Cancer: Practical Implementation Steps for Infusion Nurses

  2022cites this paper
• OCT3/4 enhances tumor immune response by upregulating the TET1-dependent NRF2/MDM2 axis in bladder cancer.

  2021cites this paper
• Clinical Outcomes of Mixed Response to Pembrolizumab in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy

  2021cites this paper
• Immune Profiling Reveals Molecular Classification and Characteristic in Urothelial Bladder Cancer

  2021cites this paper
• Immune‐related signature predicts the prognosis and immunotherapy benefit in bladder cancer

  2020cites this paper
• Screening and Identification of Key Biomarkers for Bladder Cancer: A Study Based on TCGA and GEO Data

  2020cites this paper
• BCG-Unresponsive Bladder Cancer: New Frontiers in the Treatment Landscape

  2019cites this paper
• Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy

  2019cites this paper
• Nuevos escenarios en el tratamiento con radioterapia del cáncer de vejiga

  2019cites this paper
• Personalized Bladder Cancer Management

  2018cites this paper
• STEREOTACTIC BODY RADIOTHERAPY (SBRT) AND OLIGOMETASTATIC BLADDER CANCER: ABOUT A CASE AND REVIEW OF THE LITERATURE

  2018cites this paper
• Diagnostic, Prognostic, and Predictive Biomarkers on Bladder Tissue and Blood

  2018cites this paper
• The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy

  2018cites this paper
• Pembrolizumab for the treatment of bladder cancer

  2018cites this paper
• The Rho GTPase signalling pathway in urothelial carcinoma

  2018cites this paper
• A phase I/II trial of fixed-dose stereotactic body radiotherapy with sequential or concurrent pembrolizumab in metastatic urothelial carcinoma: evaluation of safety and clinical and immunologic response

  2017influential citation
• Immunotherapy: a new treatment paradigm in bladder cancer

  2017cites this paper
• The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat

  2016cites this paper
• Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.

  2016cites this paper
• Novel therapeutic targets in advanced urothelial carcinoma.

  2016cites this paper
• Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.

  2016cites this paper
• New Agents for the Treatment of Advanced Bladder Cancer.

  2016cites this paper
• Molecular Drivers of the Non–T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer

  2016cites this paper
• Immunotherapies for bladder cancer: a new hope

  2015cites this paper
• Targeted therapies in bladder cancer: an overview of in vivo research

  2015cites this paper